Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

17.77 +0.86 (+5.09%)
Streaming Delayed Price Updated: 12:53 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
Arcturus Therapeutics: Q3 Earnings Insights
Via Benzinga
Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSE: TGT) jumped during Wednesday’s session after the company reported... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss. Cormedix posted a loss of 17 cents per share for the third... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday! 
Via InvestorPlace
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
From Arcturus Therapeutics
Via Business Wire
Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of Arcturus Therapeutics Dropped on Tuesday
The company saw revenue decline and net losses rise in the second quarter. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Dynavax Technologies Stock Sees Renewed Technical Strength
Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
3 Biotech Stocks to Buy Before the Breakout
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
3 Biotech Stocks for Getting Rich in 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.